Altogether, our findings demonstrate that tolDC can convert pro-inflammatory antigen-specific CD4+ T-cells in IA (RA and PsA) patients into anti-inflammatory Tr1 cells, which are characterised by expression of LAG3/CD49b and IL-10 production. Here, CD4 is linked to rheumatoid arthritis.